The first R&D and innovation center in China to pass the GMP inspection by USFDA

Passed USFDA site inspection with zero deficienty in Aug 2018

Welcome to SoliPharma

SoliPharma is headquartered in Hangzhou, China and has branch office in the Greater Boston area in US.
SoliPharma is recognized as National High-tech Enterprise by Ministry of Science & Technology of China, as Province-level R&D Center for Highly Variable Drugs by Department of Science & Technology of Zhejiang.
SoliPharma has been accredited ISO 17025 by CNAS since 2013. We also passed GMP site inspection by USFDA with zero deficiency in 2018.

About Us

With our track record in China/U.S./Canada/European product innovation and business relationship, SoliPharma strives for delivering both innovative products (505(b)2 with modified release/new combinations) and difficult generic products (NTI, highly variable, IP hurdles etc). Leveraging global partnership with API suppliers, contract manufacturing and product distribution, SoliPharma is devoted to bringing medical products faster to meet patients’ urgent and unmet medical needs.

Therapeutic Focus

  • Anti-infection/Immunosuppressant
  • Hematology/Blood disorder
  • Respiratory/Allergy

Leader in Specialty Pharmaceutical Products

Bring Challenging Molecules to the Global Markets

SoliPharma is a specialty pharmaceutical company. We provide technical solutions to both innovative and difficult generic products for global markets.

Excellence in Drug R&D since 2010

SoliPharma is an innovation driven company based in Hangzhou, China and Boston, U.S.

500+ Compounds

SoliPharma’s mission is to Bring Challenging Molecules to Global Markets faster and better through SoliTech® Solutions.

10000+ Testings per year

SoliPharma focuses on providing comprehensive solutions for pharmaceutical development and product registration.

500+ Customers

SoliPharma collaborates with pharmaceutical companies in Asia, North America and Europe.

image-box
2020“携手创未来”领业年度盛典

2020年1月17日,领业医药年度盛典如约而至。回顾2019,我们不忘初心,携手并进。展望2020,我们只争朝夕,不负韶华。

image-box
领业医药顺利完成B轮融资

9月20日,杭州领业医药科技有限公司与四川金石东方新材料设备股份有限公司和高雅萍女士正式签署战略投资协议。

image-box
领业团建|凝心聚力,我们向快乐出发

为了活跃气氛,增进情感交流,领业在这丹桂飘香的金秋十月,组织全体员工,18日和19日在风景秀丽的千岛湖度过一个快乐的周末。

image-box
领业零缺陷通过美国cGMP检查

2018年8月27日至29日,美国FDA检查官在对领业医药质量管理体系现场核查总结会上,直接宣布并祝贺领业医药以483零缺陷通过...

image-box
领业董事长出席胃癌国际论坛

2017年11月17日到19日,第十七届全军普通外科专业委员会学术会议暨第三届长征胃癌国际论坛于上海隆重召开。

image-box
领业成功实现片剂开发

技术服务类型:临床前处方及制剂研究,制剂工艺开发及产业化,仿制药固体制剂质量一致性评价